Effect of MD1003 in Progressive Multiple Sclerosis (SPI2)
Clinical trial NCT02936037 · TERMINATED
Trial details
- NCT number
- NCT02936037
- Sponsor
- MedDay Pharmaceuticals SA
- Status
- TERMINATED
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2016-12-01
- Primary completion
- 2019-11-15
- Enrollment
- 642
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.